Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

6.145 +0.095 (+1.57%)
Streaming Delayed Price Updated: 10:25 AM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atea Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Atea Pharmaceuticals Earnings Preview ↗
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Atea... 
Via Benzinga
News headline image
Atea Pharmaceuticals Presents Favorable AT-752 Phase 1 Data for Treatment of Dengue Fever at American Society of Tropical Medicine & Hygiene 2022 Annual Meeting
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference Call on November 7, 2022
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US ↗
 
Via Benzinga
News headline image
Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir ↗
 
Via Benzinga
News headline image
Recap: Atea Pharmaceuticals Q2 Earnings ↗
  Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Short Volatility Alert: Atea Pharmaceuticals ↗
On Tuesday, shares of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) experienced volatile short activity. After the activity, the stock price went down -1.73% to $7.38. The... 
Via Benzinga
News headline image
Atea Pharmaceuticals: Q1 Earnings Insights ↗
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion? ↗
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
News headline image
Stocks Selling For Less Than Cash Per Share ↗
How do you go about choosing a stock to buy in these volatile times? One strategy is to look for stocks that are not only selling below their book value, but also below their cash per share, especially... 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Earnings Scheduled For February 28, 2022 ↗
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
News headline image
Expert Ratings For Atea Pharmaceuticals ↗
Atea Pharmaceuticals (NASDAQ:AVIR) has observed the following analyst ratin... 
Via Benzinga
News headline image
Earnings Preview For Atea Pharmaceuticals ↗
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Atea... 
Via Benzinga
News headline image
How To Attend Atea Pharmaceuticals Q1 2022 Earnings Conference Call ↗
Atea Pharmaceuticals (NASDAQ:AVIR) will host a conference call at 10:00 AM ET on May 10, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
5 Value Stocks In The Healthcare Sector ↗
What are Value Stocks? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
News headline image
NASDAQ:AVIR Investor Notice: Investigation over Potential Wrongdoing at Atea Pharmaceuticals, Inc. ↗
San Diego, CA -- (SBWIRE) -- 04/05/2022 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Atea Pharmaceuticals, Inc. 
Via SBWire
News headline image
30 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Incannex Healthcare Limited (NASDAQ: IXHL) rose 118.2% to $49.97 in pre-market trading after jumping 54% on Monday. Incannex Healthcare recently completed a preliminary... 
Via Benzinga
News headline image
44 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) climbed 193% to $0.9962 after jumping 36% on Monday. GBS Inc. (NASDAQ: GBS) rose 73.3% to $0.7971 after declining around 9% on... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares rose 102.3% to $0.69 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.3... 
Via Benzinga
News headline image
27 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI) rose 123.4% to $0.76 in pre-market trading after jumping 36% on Monday. American Rebel Holdings, Inc. (NASDAQ: AREB) rose 28.6... 
Via Benzinga
News headline image
Atea Pharmaceuticals: Q4 Earnings Insights ↗
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Monday, February 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗
Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels. 
Via Investor's Business Daily
News headline image
NASDAQ:AVIR Investor Notice: Investigation over Possible Securities Laws Violations by Atea Pharmaceuticals, Inc. ↗
San Diego, CA -- (SBWIRE) -- 02/02/2022 -- Atea Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Atea Pharmaceuticals, Inc. (AVIR) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022 ↗
Upgrades For Canada Goose Holdings Inc (NYSE: 
Via Benzinga
News headline image
7 Pharmaceutical Stocks That Could Make You Rich ↗
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron... 
Via Benzinga
News headline image
After Roche Walks Away, Atea Puts Break On Late-Stage COVID-19 Oral Antiviral Trial ↗
Atea Pharmaceuticals Inc (NASDAQ: AVIR) said it would close the global Phase 3 MORNINGSKY trial. The decision comes after considering the changing COVID-19 landscape... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.